Safe Harbor Fiduciary’s Jazz Pharmaceuticals JAZZ Stock Holding History

Safe Harbor Fiduciary’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$170	–	121
2025 Q4	$170	Buy	+1	New	+$153	﹤0.01%	215
2025 Q2	$106	Hold	1	–	–	﹤0.01%	223
2025 Q1	$124	Hold	1	–	–	﹤0.01%	218
2024 Q4	$123	Hold	1	–	–	﹤0.01%	188
2024 Q3	$111	Buy	+1	New	+$110	﹤0.01%	204

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Safe Harbor Fiduciary's JAZZ Position: Q1 2026 in Review

Safe Harbor Fiduciary sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 1 share — an estimated $170 sold.

Safe Harbor Fiduciary first reported a position in JAZZ in Q3 2024 and held it in 5 quarters. The position peaked at $170 in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Safe Harbor Fiduciary reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Safe Harbor Fiduciary sold 1 Jazz Pharmaceuticals share in Q1 2026, an estimated $170.
Safe Harbor Fiduciary first reported a position in Jazz Pharmaceuticals in Q3 2024 and held it in 5 quarters.
Safe Harbor Fiduciary's Jazz Pharmaceuticals position peaked at $170 in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Safe Harbor Fiduciary's 13F filing for Q1 2026, filed 15 May 2026.